FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

In this video, Jamy D. Ard, MD, FTOS, discusses treatment options, lifestyle interventions and strategies for patients with obesity.

The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Join a suite of experts from across the industry Jan. 29 for a free online event examining the opportunities and challenges ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

If you've been scrolling through TikTok recently, you might have come across the "winter arc" trend — a sort of fresh take on the "new year, new me" mindset.

AI (Artificial Intelligence) letters and robot hand are placed on computer motherboard in this illustration taken, June 23, 2023. REUTERS/Dado Ruvic/Illustration/File Photo A look at the day ahead ...